Trial Profile
A Phase I Study of OSI-774 in Combination With Gemcitabine and Radiation in Locally Advanced, Non-Operable Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2013
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 May 2007 Status changed from in progress to completed.
- 19 Jan 2007 Status changed from recruiting to in progress.